S&P 500 -150% -50% 50% 150% 250% 350% 450% 550% POL S&P 500 All time high of $43.34 July 1st, 2014 PolyOne Corporation Page 9 2006 2014 YTD 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 14.9% 12 – 16% Global Specialty Engineered Materials 1.1% 12.1% 12 – 16% Designed Structures & Solutions -- 7.6% 8 – 10% Performance Products & Solutions 5.5% 8.1% 9 – 12% Distribution 2.6% 6.2% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 65% 65 – 75% 3) ROIC* 5.0% 10.6% 15% 4) Adjusted EPS Growth N/A 37% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period PolyOne Corporation Page 10 32% Adjusted EPS CAGR from 2011 2015 EPS: $2.50 2011 EPS: $0.82 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental Share Buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid Single Digit Revenue Growth PolyOne Corporation Page 11 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14% 31% 2006 2013 Specialty Platform Gross Margin % 20% 43% 2006 2013 Specialty Vitality Index Target ≥ 35% Vitality Products + 700 to 1000 bps PolyOne Corporation Page 12 Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 4 11 5 10 6 9 3 4 2 15 9 1 10 4 Breakthrough Platform Derivative A Rich Pipeline of Opportunity Number of Projects 25 14 19 17 18 93 Addressable Market ($ millions) TBD TBD $800 $450 $450 $1,700 PolyOne Corporation Page 13 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 14 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of 2014年9月30日 Debt Maturities & Pension Funding – 9/30/14 Net Debt / EBITDA* = 1.7x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of 2014年9月30日 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 9/30/2014 PolyOne Corporation Page 15 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return Expanding our sales, marketing, and technical capabilities Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin Synergy opportunities Adjacent material solutions Repurchased 1.5 million shares in Q3 2014 Repurchased 9.7 million shares since early 2013 10.3 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture) Manufacturing alignment $0.16 $0.20 $0.24 $0.32 $0.40 $0.10 $0.20 $0.30 $0.40 $0.50 2011 2012 2013 2014 2015 Annual Dividend PolyOne Corporation Page 16 PolyOne Core Values Innovation Collaboration Excellence PolyOne Corporation Page 17 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? ��PolyOne Investor Presentation�Goldman Sachs 2014 US Emerging / SMID Cap Growth Conference�New York, NY�2014年11月20日�� Forward-Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results Proof of Performance & 2015 Goals 32% Adjusted EPS CAGR from 2011 Innovation Drives Earnings Growth A Rich Pipeline of Opportunity Megatrends Aligned with Key End Markets Debt Maturities & Pension Funding – 9/30/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return PolyOne Core Values Why Invest In PolyOne?

Safety Data Sheets Technical Data Sheets Browse our library of product data sheets containing technical descriptions and details.

Safety Data Sheets Technical Data Sheets ECCOH™ Thermoplastic Formulation provided anti-fungi and flame retardant solutions to optical cable sheath

PROCESS OVERVIEW Polystrand™ advanced thermoplastic composites combine high strength, unidirectional, continuous fibers with engineered thermoplastic resins to create continuous fiber reinforced thermoplastic (CFRTP) materials that feature exceptional strength-to-weight ratio and high impact resistance. Overmolding integrates Polystrand tapes and multi- ply laminates into traditional thermoplastic molding processes, such as injection and compression molding, to create locally-reinforced, molded components. Overmolding with Polystrand™ Continuous Fiber Reinforced Thermoplastic Composites Processability Meets Performance Overmolding with Polystrand CFRTP can enhance the performance of traditional thermoplastics or enable metal replacement in a wide range of applications.

R E S I D E N T I A L BU I L D I N G M A N U FA C T U R E R M O D U L A R W A L L C O N S T R U C T I O N • Technical expertise to provide a custom composite panel that meets performance requirements • High strength-to-weight ratio compared to incumbent materials • High impact resistance, durability, and structural integrity • On-site technical support with product development, including rigorous material sampling and testing • Custom-formulated panel structures meeting impact and lightweight requirements • Technical capabilities to provide a solution meeting residential fire testing Polystrand™ Thermoplastic Composite Panels KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/advanced-composites/continuous-fiber-composite-panels/polystrand-thermoplastic-composite-panels

DEVICE MANUFACTURER M E D I C A L D E V I C E H O U S I N G • Improved chemical resistance compared to PC/ABS, PC/PET & COPE • Flame retardant (FR) rating of V-1 at 0.75 mm • Zero BPA & non-halogenated FR material • Available in standard hospital grade pre-colors • Provided a cost-effective material with superior chemical resistance to traditional materials • Formulated a medical-grade, semi-crystalline blend to support regulatory testing and approvals • Demonstrated superior property retention and crack resistance after exposure to hospital- grade disinfectants, including Virex® Tb, helping to extend the device life Trilliant™ HC8900 Thermoplastics KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics

M E D I C A L C O N T R AC T M A N U FAC T U R E R A U T O - I N J E C T O R H O U S I N G • Excellent chemical and wear resistance • Excellent impact resistance • Specific color matching based on customer’s needs • Outstanding durability to extend product life • Customized a chemically resistant formulation to offer an impact-modified alternative to traditional competitors in the market • Provided technical support for material selection, part & tool design, and process development to accelerate commercialization • Delivered custom color matching to meet all key requirements Custom Trilliant™ HC Healthcare Thermoplastic KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics

B I O P H A R M AC E U T I C A L S U P P LY C O M PA N Y T U B I N G C L A M P • High impact and wear resistance • Low moisture uptake • Comparable dimensional stability to nylon • Eco-conscious alternative to PA66 and PA6 • Delivered a comparable alternative to nylons during supply shortages, resulting in rugged performance and a lower carbon footprint • Provided improved chemical resistance to nylon clamps to withstand repeated cleanings from harsh disinfectants • Offered a global manufacturing footprint to support future expansion of the end products to markets outside the Americas Trilliant™ HC 8910 Glass-Filled Polyketone Thermoplastics KEY REQUIREMENTS WHY AVIENT AVIENT SOLUTION DURABILITY + MATERIAL AVAILABILITY LEARN MORE Copyright © 2023, Avient Corporation. https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics

Trilliant HC - OCD Microwells IVD Testing - Application Snapshot ORTHO CLINICAL DIAGNOSTICS M I C R O W E L L S F O R I V D D E V I C E • PS-based material • Strict TiO2 content/filling to secure accurate performance • Material to be suitable and complaint with the IVDD/IVDR standards • Surface chemical performance essential for the application • Worked in close collaboration with customer and internal teams to fully understand and overcome current material challenges • Identified anomalies in existing formulation using material science expertise and customized an alternative formulation • Enabled customer to improve processing efficiency, reduce scrap rate and respond to the increased market demand Trilliant™ HC7410-5001 X4 thermoplastics in white KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics

https://www.avient.com/products/thermoplastic-elastomers/versaflex-thermoplastic-elastomers